BioDelivery Sciences International,... (BDSI)
$5.59
Rating:
Recommendation:
Neutral
| Symbol | BDSI |
|---|---|
| Price | $5.59 |
| Beta | 0.000 |
| Volume Avg. | 3.35M |
| Market Cap | 577.050M |
| Shares () | - |
| 52 Week Range | 2.5-5.62 |
| 1y Target Est | - |
| DCF Unlevered | BDSI DCF -> | |
|---|---|---|
| DCF Levered | BDSI LDCF -> | |
| ROE | 57.33% | Strong Buy |
| ROA | 26.14% | Buy |
| Operating Margin | - | |
| Debt / Equity | 31.30% | Neutral |
| P/E | 6.82 | Buy |
| P/B | 2.96 | Strong Buy |
Latest BDSI news
About
Download (Excel)BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.